Outcomes Research: A Methodologic Review

European Urology

Volumn 50, Issue 2, 2006, Pages 218-224

  Karakiewicz, Pierre I ^a   Briganti, Alberto ^a   Chun, Felix K H ^a   Valiquette, Luc ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cancer control; Decision making; Models; Outcomes research; Prognostics; Quality of life

Indexed keywords

COST BENEFIT ANALYSIS; ERECTILE DYSFUNCTION; ETHNOLOGY; GEOLOGY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; INFORMATION TECHNOLOGY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT CARE; POLITICS; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RACE; REVIEW; TAXONOMY; URINE INCONTINENCE;

HUMANS; NOMOGRAMS; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATECTOMY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; UROLOGY;

EID: 33745865539     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.05.009     Document Type: Review

References (53)

1. Youngs M.T., and Wingerson L. The 1996 medical outcomes & guidelines sourcebook (1995), Faulkner & Gray, Inc, New York
2. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
3. Lotan Y., Cadeddu J.A., Lee J.J., Roehrborn C.G., and Lippman S.M. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol 23 (2005) 1911-1920
4. Codman E.A. The product of a hospital. Surg Gynecol Obstet 18 (1914) 491-496
5. Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 44 (1966) 166-206
6. Cochrane A.L. Archie Cochrane in his own words. Selections arranged from his 1972 introduction to 'Effectiveness and Efficiency: Random reflections on health services' 1972. Control Clin Trials 10 (1989) 428-433
7. Wennberg J., and Gittelsohn A. Small area variations in health care delivery. Science 182 (1973) 1102-1108
8. Epstein A.M. The outcomes movement-will it get us where we want to go?. N Engl J Med 323 (1990) 266-267
9. Agency for Health Care Policy and Research. Patient outcomes research teams (PORTs). Available from: http://www.ahcpr.gov/news/ports99.htm.
10. Agency for Health Care Policy and Research. Current patient outcomes research teams (PORT-IIs). Available from: http://www.ahcpr.gov/news/portii99.htm.
11. National Cancer Institute. Surveillance Epidemiology and End Results. Available from: http://seer.cancer.gov.
12. National Cancer Institute. The prostate cancer outcomes study. Available from: http://seer.cancer.gov/studies/endresults/study24.html.
13. Potosky A.L., Davis W.W., Hoffman R.M., et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96 (2004) 1358-1367
14. American Society of Clinical Oncology. Committee: Health Services Research (HSR). Available from: http://asco.infostreet.com/prof.
15. American Society of Therapeutic Radiation Oncologists. ASTRO Committees. Available from: http://www.astro.org/about.
16. National Cancer Institute. Applied research: outcomes research. Available from: http://www-dccps.ims.nci.nih.gov/ARB.
17. Lee S.J., Earle C.C., and Weeks J.C. Outcomes research in oncology: history, conceptual framework, and trends in the literature. J Natl Cancer Inst 92 (2000) 195-204
18. Zeliadt S.B., Potosky A.L., Etzioni R., Ramsey S.D., and Penson D.F. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 64 (2004) 1171-1176
19. Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality. Overview of the Nationwide Inpatient Sample (NIS). Available from: http://www.hcup-us.ahrq.gov/nisoverview.jsp.
20. Karakiewicz P.I., Zini A., Meshref A.W., Bazinet M., Aprikian A.G., and Elhilali M.M. Population-based patterns of radical retropubic prostatectomy use. Urology 52 (1998) 219-223
21. Karakiewicz P.I., Bazinet M., Aprikian A.G., Tanguay S., and Elhilali M.M. Thirty-day mortality rates and cumulative survival after radical retropubic prostatectomy. Urology 52 (1998) 1041-1046
22. Karakiewicz P.I., Tanguay S., Kattan M.W., Elhilali M.M., and Aprikian A.G. Erectile and urinary dysfunction after radical prostatectomy for prostate cancer in Quebec: a population-based study of 2415 men. Eur Urol 46 (2004) 188-194
23. Lu-Yao G.L., and Greenberg E.R. Changes in prostate cancer incidence and treatment in USA. Lancet 343 (1994) 251-254
24. Lu-Yao G., Albertsen P.C., Stanford J.L., Stukel T.A., Walker-Corkery E.S., and Barry M.J. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325 (2002) 740
25. Kattan M.W., Cowen M.E., and Miles B.J. A decision analysis for treatment of clinically localized prostate cancer. Gen Intern Med 12 (1997) 299-305
26. Cowen M.E., Miles B.J., Cahill D.F., Giesler R.B., Beck J.R., and Kattan M.W. The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making 18 (1998) 376-380
27. Ramirez A, Benayoun S, Briganti A, et al. High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. Eur Urol. 2006;50:58-63.
28. Litwin M.S., Hays R.D., Fink A., Ganz P.A., Leake B., and Brook R.H. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 36 (1998) 1002-1012
29. Wei J.T., Dunn R.L., Litwin M.S., Sandler H.M., and Sanda M.G. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000) 899-905
30. Esper P., Mo F., Chodak G., Sinner M., Cella D., and Pienta K.J. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50 (1997) 920-928
31. Lubeck D.P., Grossfeld G.D., and Carroll P.R. A review of measurement of patient preferences for treatment outcomes after prostate cancer. Urology 60 (2002) 72-77
32. Karakiewicz P.I., Kattan M.W., Tanguay S., et al. Cross-cultural validation of the UCLA prostate cancer index. Urology 61 (2003) 302-307
33. Litwin M.S., Shpall A.I., Dorey F., and Nguyen T.H. Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 21 (1998) 327-332
34. Voogt E., van der Heide A., Rietjens J.A., et al. Attitudes of patients with incurable cancer toward medical treatment in the last phase of life. J Clin Oncol 23 (2005) 2012-2019
35. Gandek B., Ware J.E., Aaronson N.K., et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 51 (1998) 1171-1178
36. Ware J.E., Kosinski M., Dewey J.E., and Gandek B. How to score and interpret single-item health status measures: a manual for users of the SF-8 health survey (2001), Quality Metric Incorporated, Lincoln (RI)
37. Lebeau T., Perrotte P., Valiquette L., et al. Validation of prostate cancer index and SF-12 short forms. Can J Urol 12 (2005) 2873-2879
38. Ross P.L., Littenberg B., Fearn P., Scardino P.T., Karakiewicz P.I., and Kattan M.W. Paper standard gamble: a paper-based measure of standard gamble utility for current health. Int J Technol Assess Health Care 19 (2003) 135-147
39. Fleming S.T., Pearce K.A., McDavid K., and Pavlov D. The development and validation of a comorbidity index for prostate cancer among Black men. J Clin Epidemiol 56 (2003) 1064-1075
40. Gospodarowicz M.K., Miller D., Groome P.A., Greene F.L., Logan P.A., and Sobin L.H. The process for continuous improvement of the TNM classification. Cancer 100 (2004) 1-5
41. Partin A.W., Mangold L.A., Lamm D.M., Walsh P.C., Epstein J.I., and Pearson J.D. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
42. Karakiewicz P.I., Benayoun S., Kattan M.W., et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 173 (2005) 1930-1934
43. Cagiannos I., Karakiewicz P., Eastham J.A., et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170 (2003) 1798-1803
44. Graefen M., Karakiewicz P.I., Cagiannos I., et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 20 (2002) 3206-3212
45. Svatek R., Karakiewicz P.I., Shulman M., Karam J., Perrotte P., and Benaim E. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer. Eur Urol 49 (2006) 666-674
46. Anagnostou T., Remzi M., Lykourinas M., and Djavan B. Artificial neural networks for decision-making in urologic oncology. Eur Urol 43 (2003) 596-603
47. Kattan M.W. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol 170 (2003) S6-S9
48. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
49. Steuber T., Graefen M., Haese A., et al. Validation of a nomogram for prediction of side-specific extracapsular extension at radical prostatectomy. J Urol 175 (2006) 939-944
50. Graefen M., Karakiewicz P.I., Cagiannos I., et al. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol 7 (2002) 141-146
51. Specht M.C., Kattan M.W., Gonen M., Fey J., and Van Zee K. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 12 (2005) 654-659
52. Kattan M.W. Statistical prediction models, artificial neural networks, and the sophism "I am a patient, not a statistic". J Clin Oncol 20 (2002) 885-887
53. Weinfurt K.P. Outcomes research related to patient decision making in oncology. Clin Ther 25 (2003) 671-683